Clovis Oncology PE Ratio 2010-2021 | CLVS

Current and historical p/e ratio for Clovis Oncology (CLVS) from 2010 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Clovis Oncology PE ratio as of September 23, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Clovis Oncology PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-09-23 4.61 0.00
2021-06-30 5.80 $-3.16 0.00
2021-03-31 7.02 $-3.70 0.00
2020-12-31 4.80 $-4.45 0.00
2020-09-30 5.83 $-5.24 0.00
2020-06-30 6.75 $-6.07 0.00
2020-03-31 6.36 $-7.19 0.00
2019-12-31 10.43 $-7.43 0.00
2019-09-30 3.93 $-7.50 0.00
2019-06-30 14.87 $-7.49 0.00
2019-03-31 24.82 $-7.16 0.00
2018-12-31 17.96 $-7.07 0.00
2018-09-30 29.37 $-6.23 0.00
2018-06-30 45.47 $-5.76 0.00
2018-03-31 52.80 $-7.70 0.00
2017-12-31 68.00 $-7.49 0.00
2017-09-30 82.40 $-8.28 0.00
2017-06-30 93.63 $-8.74 0.00
2017-03-31 63.67 $-8.23 0.00
2016-12-31 44.42 $-9.07 0.00
2016-09-30 36.05 $-10.36 0.00
2016-06-30 13.72 $-11.28 0.00
2016-03-31 19.20 $-10.01 0.00
2015-12-31 35.00 $-9.70 0.00
2015-09-30 91.99 $-8.20 0.00
2015-06-30 87.88 $-6.75 0.00
2015-03-31 74.23 $-5.68 0.00
2014-12-31 56.00 $-4.73 0.00
2014-09-30 45.36 $-4.03 0.00
2014-06-30 41.41 $-3.54 0.00
2014-03-31 69.27 $-3.23 0.00
2013-12-31 60.27 $-2.92 0.00
2013-09-30 60.80 $-2.81 0.00
2013-06-30 66.98 $-2.84 0.00
2013-03-31 28.67 $-2.73 0.00
2012-12-31 16.00 $-2.99 0.00
2012-09-30 20.45 $-3.48 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.526B $0.165B
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71